Gene therapy represents a paradigm shift in modern medicine, offering unprecedented opportunities to combat diseases at their ...

A promising approach includes the reconstruction of functional molecular networks through the integration of high-quality information from functional genomics and proteomics data (Fig. 5).

Artificial intelligence (AI) has emerged as a powerful toolset that could create new opportunities and help overcome hurdles in proteomics and wider omics disciplines. Bolstered by AI, these fields of ...

Dante Genomics, a global leader in AI-driven genomic analysis, has expanded into Dante Omics AI to reflect its evolution into ...

New next generation sequencing-based proteomics kits designed to integrate with multiple NGS platforms, eliminating the need for new instrumentation or specialized expertise Thermo Fisher ...

Proteomics and metabolomics are unlocking new dimensions in biology and disease research and this fifth annual event will showcase the most cutting-edge advancements in the field. Gain expert insights ...

A major population proteomics study using UK Biobank patient samples backed by 14 pharma companies has launched today with the promise of delivering a "transformation" in the study of diseases and ...

Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company ™, announces the formation of its Scientific Advisory Board. Comprised of distinguished experts in ...

Metabolite profiling is an integral component of systems biology, an exciting field that combines genomics, transcriptomics and proteomics to define cellular functionality. Our scientists empower ...

The new study adds to growing evidence that measuring activated proteins is key to cancer therapy selection.Golden, CO, Feb. 10, 2025 (GLOBE ...

enabling seamless integration of proteomics with genomic and transcriptomic research. As the Festival of Genomics UK continues to drive conversation and innovation within the genomics community ...

Barclays downgraded Illumina Inc (NASDAQ:ILMN) to "Underweight" given growing uncertainty in China, rising competition from Roche in the clinical market, and weaker-than-expected elasticity in ...